文献速递头颈与中枢神经肿瘤支持与姑息治疗

普瑞巴林对头颈癌患者放疗相关神经病理性疼痛的影响:一项随机对照试验

Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial.
PubMed 文献 · J Clin Oncol · 2018-11-20

这项在中国四中心开展的随机双盲安慰剂对照试验纳入128例头颈癌放疗相关神经病理性疼痛患者,评估普瑞巴林与安慰剂的疗效与安全性。第16周时普瑞巴林组疼痛强度降低2.44,安慰剂组降低1.58,校正均差0.87(95%CI 0.30~1.44;P=.003)。普瑞巴林组疼痛缓解≥30%和≥50%的患者比例均高于安慰剂组,情绪状态与生活质量亦改善,两组不良事件发生率无显著差异。

要点

  • 第16周疼痛强度降低普瑞巴林组2.44 vs 安慰剂组1.58,校正均差0.87(95%CI 0.30~1.44;P=.003)。
  • 疼痛缓解≥30%者普瑞巴林组38例(59.4%)vs 安慰剂组21例(32.8%)(P=.006)。
  • 两组至少发生1次不良事件的比例无显著差异(P=.29)。

核心结论

  • 接受普瑞巴林治疗的头颈癌放疗相关神经病理性疼痛患者较安慰剂组疼痛缓解更明显、情绪状态更好、生活质量更高,且耐受性良好。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,在中国四个中心开展。
  • 纳入11点数字评定量表平均疼痛强度评分≥4分的合格患者,随机接受弹性剂量普瑞巴林或安慰剂治疗16周。
  • 共128例患者按随机分配接受治疗。
  • 主要疗效终点为数字评定量表测量的疼痛减轻程度。

主要发现

  • 第16周疼痛强度降低普瑞巴林组为2.44,安慰剂组为1.58,校正均差0.87(95%CI 0.30~1.44;P=.003)。
  • 普瑞巴林组38例(59.4%)达到至少30%疼痛缓解,安慰剂组21例(32.8%)(P=.006)。
  • 普瑞巴林组19例(29.7%)达到50%或以上疼痛缓解,安慰剂组5例(7.8%)(P=.003)。
  • 第16周时普瑞巴林组较安慰剂组在简明心境量表总分、简明疼痛评估量表疼痛严重程度与功能干扰、WHO生活质量简表生理与心理领域评分均显著降低。
  • 至少发生1次不良事件的发生率普瑞巴林组(n=35;54.7%)与安慰剂组(n=29;45.3%)无显著差异(P=.29)。

临床怎么用

  • 原文结论为普瑞巴林组较安慰剂组疼痛缓解更明显、情绪状态更好、生活质量更高,且耐受性良好。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Neuropathic pain is an unavoidable treatment-related adverse event among patients with head and neck cancer who are undergoing radiotherapy. We aimed to test the efficacy and safety of pregabalin versus placebo in the treatment of radiotherapy-related neuropathic pain. PATIENTS AND METHODS: This randomized, double-blind, placebo-controlled trial was conducted in four centers in China. Eligible patients with a mean pain intensity score of 4 or more on an 11-point numeric rating scale were randomly assigned to receive either active treatment with a flexible dose of pregabalin or placebo for 16 weeks. The primary efficacy outcome was pain reduction measured on the numeric rating scale. RESULT: There were 128 patients who received treatment as randomly assigned. Pain intensity reduction was 2.44 in the pregabalin arm and 1.58 in the placebo arm at week 16, yielding an adjusted mean difference of 0.87 (95% CI, 0.30 to 1.44; P = .003). In the pregabalin arm, 38 patients (59.4%) achieved at least 30% pain relief versus 21 (32.8%) in the placebo arm ( P = .006). Nineteen patients (29.7%) in the pregabalin group and five (7.8%) in the placebo group achieved 50% or greater pain relief ( P = .003). Total scores on the Profile of Mood States-Short Form, pain severity and functional interference of Brief Pain Inventory-Short Form, as well as the physiology and psychology domain of the WHO Quality of Life-BREF all were reduced significantly at week 16 in patients who received pregabalin compared with those who received placebo. There was no significant difference ( P = .29) in the incidence of experiencing at least one adverse event in the pregabalin arm (n = 35; 54.7%) versus the placebo arm (n = 29; 45.3%). CONCLUSION: Patients treated with pregabalin with radiotherapy-related neuropathic pain had greater pain alleviation, better mood states, and higher quality of life compared with patients in the placebo group, with a good tolerability.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jiang J, Li Y, Shen Q, et al. Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial. J Clin Oncol. 2018. PMID: 30457920. doi:10.1200/JCO.18.00896

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。